Recent studies reported cases of MLL–AF4 rearranged pro-B-ALL patients treated with blinatumomab, a bispecific antibody that targets CD19 on B-cells, who relapsed with AML (52–54). This evidence concerns the gene KMT2A and acute myeloid leukemia.